Checkpoint Therapeutics Inc’s recent filing unveils that its CEO, President and Director Oliviero James F III unloaded Company’s shares for reported $2.33 million on Dec 18 ’24. In the deal valued at $3.87 per share,602,167 shares were sold. As a result of this transaction, Oliviero James F III now holds 3,414,813 shares worth roughly $10.24 million.
Then, Oliviero James F III sold 220,230 shares, generating $744,377 in total proceeds. Upon selling the shares at $3.38, the CEO, President and Director now owns 3,194,583 shares.
Before that, GRAY WILLIAM GARRETT sold 268,432 shares. Checkpoint Therapeutics Inc shares valued at $1,076,412 were divested by the Chief Financial Officer at a price of $4.01 per share. As a result of the transaction, GRAY WILLIAM GARRETT now holds 1,032,754 shares, worth roughly $3.1 million.
D. Boral Capital initiated its Checkpoint Therapeutics Inc [CKPT] rating to a Buy in a research note published on January 13, 2025; the price target was $9. B. Riley Securities began covering CKPT with “Buy” recommendation on June 09, 2021. Cantor Fitzgerald started covering the stock on January 20, 2021. It rated CKPT as “an Overweight”.
Price Performance Review of CKPT
On Tuesday, Checkpoint Therapeutics Inc [NASDAQ:CKPT] saw its stock fall -5.66% to $3.00. Over the last five days, the stock has lost -6.25%. Checkpoint Therapeutics Inc shares have fallen nearly -6.25% since the year began. Nevertheless, the stocks have risen 64.84% over the past one year. While a 52-week high of $4.50 was reached on 01/06/25, a 52-week low of $1.38 was recorded on 01/21/25. SMA at 50 days reached $3.60, while 200 days put it at $2.55.
Levels Of Support And Resistance For CKPT Stock
The 24-hour chart illustrates a support level at 2.91, which if violated will result in even more drops to 2.83. On the upside, there is a resistance level at 3.13. A further resistance level may holdings at 3.26. The Relative Strength Index (RSI) on the 14-day chart is 38.29, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.48%. Stochastics %K at 12.29% indicates the stock is a buying.
How much short interest is there in Checkpoint Therapeutics Inc?
A steep rise in short interest was recorded in Checkpoint Therapeutics Inc stocks on 2024-10-31, growing by 1.19 million shares to a total of 5.56 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 4.38 million shares. There was a rise of 21.35%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 29, 2019 when Lake Street began covering the stock and recommended ‘”a Buy”‘ rating .
